1 Department of Hematology, Oncology and Blood and Marrow Transplantation, The Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
2 Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
3 Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington, USA.
4 Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA neeraj.agarwal@hci.utah.edu.
This commentary reviews current progress in neoadjuvant immunotherapy for muscle‐invasive localized urothelial carcinoma, highlighting opportunities and challenges with recent neoadjuvant immunotherapy trials.